REG - Aptamer Group PLC - Material Agreement with Genetic Medicines Company

AptamerAnnouncement

14/12/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231214:nRSN7178Wa&default-theme=true

RNS Number : 7178W  Aptamer Group PLC  14 December 2023

14 December 2023

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Aptamer Group signs material agreement with genetic medicines company

-       Optimer binders will be developed to support targeted genetic
medicines to specific cell types

-       Contract comprises up to £553k in development fees for Aptamer
Group

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, announces that it has
entered into a material agreement with a biotechnology company developing
genetic medicines.

 

Under the terms of the agreement, Aptamer Group will use its proprietary
platform to discover Optimer binders to enable the specific targeting of
genetic medicines to specific cell types. Aptamer Group will receive up to
£553,000 in development fees for discovering and developing the Optimer
binders. Work is expected to commence shortly subject to receiving target
materials from the customer and is expected to be completed within the current
financial year.

 

Optimer binders are a novel class of molecules for selectively targeting new
biomarkers and tissues. Optimers are fully synthetic oligonucleotide molecules
that offer a controlled development process, delivering high affinity and
highly selective binders, which makes them attractive candidate molecules for
drug delivery. The smaller size of Optimers allows for improved tissue
penetration, enabling effective therapeutic delivery, while the ability to
control Optimer conjugation to therapeutic payloads allows precision in
therapeutic development and dosing of payloads.

 

Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said: "This project
builds on the work we have been doing in drug delivery since being refunded
and supports the need for new delivery modalities within the genetic medicines
space. Targeting oligonucleotide therapeutics beyond hepatocytes remains a
challenge across the industry; we believe the properties of Optimers make them
suitable for developing precision-guided therapies and that Optimer-targeted
therapies may represent the next stage in targeted drug delivery."

 

- ENDS -

 

For further information, please contact:

 

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Steve Hull
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Mark Brady / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker

 

About Aptamer Group plc

Aptamer Group develops custom affinity binders through its proprietary
Optimer(®) platform to enable new approaches in therapeutics, diagnostics,
and research applications. The Company strives to deliver transformational
solutions that meet the needs of life science researchers and developers.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion.

Aptamer has successfully delivered projects for a range of global pharma
companies, diagnostic development companies, and research institutes, covering
multiple application areas with the objective of establishing royalty-bearing
licenses.

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRGZMMZZFGGFZZ